NNC6019-0001 + Placebo (NNC6019-0001)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Conditions
Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Trial Timeline
Aug 2, 2022 → May 13, 2025
NCT ID
NCT05442047About NNC6019-0001 + Placebo (NNC6019-0001)
NNC6019-0001 + Placebo (NNC6019-0001) is a phase 2 stage product being developed by Novo Nordisk for Transthyretin Amyloid Cardiomyopathy (ATTR CM). The current trial status is completed. This product is registered under clinical trial identifier NCT05442047. Target conditions include Transthyretin Amyloid Cardiomyopathy (ATTR CM).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07207811 | Phase 3 | Recruiting |
| NCT05442047 | Phase 2 | Completed |
Competing Products
20 competing products in Transthyretin Amyloid Cardiomyopathy (ATTR CM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 33 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| Treatment of transthyretin (ATTR) amyloidosis in observational study setting | AstraZeneca | Pre-clinical | 23 |
| Eplontersen | AstraZeneca | Phase 3 | 77 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 77 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 76 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 51 |
| Coramitug | Novo Nordisk | Phase 1 | 32 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| tafamidis meglumine | Pfizer | Approved | 84 |
| Fx-1006A | Pfizer | Phase 2 | 51 |
| Tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 22 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 22 |
| Vyndaqel | Pfizer | Pre-clinical | 22 |
| tafamidis | Pfizer | Phase 3 | 76 |
| Tafamidis | Pfizer | Approved | 84 |
| Tafamidis | Pfizer | Pre-clinical | 22 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 22 |